Chemotherapy right after surgery for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk bladder cancer that has not reached the muscle layer.
- Your cancer includes features like high-grade tumors, tumor larger than 3 cm, multiple tumors, carcinoma in situ, or other concerning features.
- You are in generally good health and can be followed for 2 years.
- You have not had previous chemotherapy, immunotherapy, or radiation for bladder cancer.
- You do not have other serious medical conditions like active infections or low blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
This trial tests whether giving chemotherapy before surgery can help people with high-risk upper tract urothelial cancer (a cancer in the kidney or ureter). The goal is to see if it improves outcomes for those who are healthy enough to receive cisplatin-based chemotherapy and undergo surgery.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
This study compares two approaches for people with early-stage bladder cancer that has a low chance of coming back: either careful monitoring without immediate treatment, or receiving chemotherapy directly into the bladder to lower the risk of recurrence. It aims to see if monitoring alone is as good as chemotherapy for those with a low risk detected by a urine test.
This trial looks at whether giving chemotherapy before surgery helps people with muscle invasive bladder cancer live longer. It is for patients who haven't had surgery yet and whose cancer hasn't spread.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.